The National Institute of Clinical Excellence (NICE, United Kingdom) and other regulatory bodies such as the European Society of Cardiology recommends ACEIs and β-blockers as first-line treatment for HF (Al-Mohammad et al., 2010; Ponikowski et al., 2016); however, dysregulation of Ca2+ handling proteins occurs exclusively during pathological hypertrophy (and not physiological hypertrophy) which suggests altered Ca2+ cycling and signaling precedes Ca2+ dysregulation observed in HF. Here, CA2 is linked to hydrops fetalis.